



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification: \_\_\_\_\_ Attorney's  
of this Application: Examr Mary M. Schmidt Docket No.: **Enz-53(D4)(FWC)**  
Class \_\_\_\_\_ Subclass \_\_\_\_\_ Group Art Unit: **Not Yet Known**  
Prior Group Art Unit: **1635**

**FILED BY FIRST CLASS MAIL**

Hon. Commissioner of Patents and Trademarks  
Washington, D.C. 20231  
**BOX FWC (if under §1.62)**  
Sir:

#16  
SQ  
6/1/00

This is a request for filing a   X   CONTINUATION        DIVISIONAL         
CONTINUATION-IN-PART application under        37 CFR §1.60   X   37 CFR §1.62,  
of pending prior application Serial No. 08/978,635 filed on November 25, 1997  
Elazar Rabbani et al.

Inventor(s)  
for: **PROCESS FOR SELECTIVE EXPRESSION OF NUCLEIC ACID  
CONSTRUCTS (As Previously Amended)**  
Title of Invention


1. \_\_\_\_\_ Enclosed is a copy of the prior application, as originally filed and an affidavit or declaration verifying it as a true copy.
2. \_\_\_\_\_ A copy of the verified statement under 37 CFR §1.9 and §1.27 establishing small entity status in the prior application is enclosed. Small entity status is still applicable.
3.   X   The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT								
					RATE			FEE
	Number Filed		Number Extra		Small Entity	Other Entity		Small Entity    Other Entity
Total Claims	7	=	0	x	\$ 9	\$ 18	=	\$ 0    \$ 690-
Independent Claims	1	=	0	x	\$ --	\$ 78	=	\$ 0    \$ ---
Multiple Dependent Claims Presented <u>      </u> Yes <u>      </u> No					\$130	\$260		\$    \$ ---
If the difference in Col. 1 is less than zero, enter "0" in Col. 2						BASIC FEE		\$345    \$690
						TOTAL FEE		\$345    \$ 0

15 01/2000 STEFERRA 00000007 051135 08978635  
01 701831 345.00 CH

4.   X   The Commissioner is hereby authorized to charge payment of the filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No. 05-1135. A **duplicate** copy of this sheet is enclosed.
- X   Any additional filing fees required under 37 CFR §1.16.
- X   Any patent application processing fees under 37 CFR §1.17.

Attorney's Docket No. Enz-53(D4)(FWC)



5.   X   The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 05-1135. A **duplicate** copy of this sheet is enclosed.
- X   Any patent application processing fees under 37 CFR §1.17.  
       The issue fee set in 37 CFR §1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR §1.311(b).  
       Any filing fees under 37 CFR §1.16 for presentation of extra claims.
6.        A check in the amount of \$        is enclosed.
7.        Cancel claims       .
8.   X   Amend the specification by inserting before the first line of the sentence: --- This is a   X   continuation,        divisional,        continuation-in-part, of application Serial No. 08/978,635, filed on November 25, 1997. ---
9.        Transfer the drawings from the prior application.
10.        Informal        Formal        drawings are enclosed.
11.        Abandon said prior application as of the filing date accorded this application. A **duplicate** copy of this sheet is enclosed for filing in the prior application file.
12.        Priority of application Serial No.        filed on        is claimed under 35 U.S.C. §119.  
The certified copy of the priority application has been filed in prior application Serial No.       , filed       .
13.        The prior application is assigned of record to Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022. [A copy of the originally submitted Assignment and the Notice of Recordation are enclosed herewith.]
14.        A preliminary amendment is enclosed.
15.   X   The power of attorney in the prior application is to:  
Ronald C. Fedus, Reg. No. 32,567.
- (a)   X   The power appears in the original papers in the prior application.
- (b)        Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- (c)        A copy of a new substitute power of attorney is enclosed.

(d) X Address all future communications to: (May only be  
completed by applicant, or attorney or agent of  
record.)


Ronald C. Fedus, Esq.  
Enzo Therapeutics, Inc.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9th Floor)  
New York, New York 10022

16. \_\_\_\_\_ I hereby verify that the attached papers are a true copy of prior  
application Serial No. \_\_\_\_\_.

The undersigned declares further that all statements made herein of his own knowledge  
are true and that all statements made on information and belief are believed to be true;  
and further that these statements were made with the knowledge that willful false  
statements and the like so made are punishable by fine or imprisonment, or both, under  
Section 1001 of Title 18 of the United States Code and that such willful false statements  
may jeopardize the validity of the application or any patent issuing thereon.

May 23, 2000

Date



Ronald C. Fedus  
Registration No. 32, 567  
Attorney for Applicants

\_\_\_\_ Inventor(s)  
\_\_\_\_ Assignee of Complete Interest  
X Attorney or Agent of Record  
\_\_\_\_ Filed under 37 CFR §1.34(a)

Address of Signator:  
Enzo Therapeutics, Inc.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9th Floor)  
New York, New York 10022